Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Rani Therapeutics to Participate in the Evercore Healthcare Conference
Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update